The Lancet SELECT Trial: Semaglutide 2.4mg and Cardiovascular Risk Reduction in Obesity

Lancet Insights | 2026-07-12 | 12 min read

Analysis of The Lancet SELECT trial demonstrating semaglutide 2.4mg weekly reduced cardiovascular events by 20% in patients with obesity but without diabetes, establishing GLP-1 therapy for primary cardiovascular prevention.

The SELECT Trial: A Landmark in Cardiovascular Prevention

The Lancet published the SELECT trial results in August 2024, representing a watershed moment in cardiovascular medicine. This landmark study demonstrated that semaglutide 2.4mg weekly reduces major adverse cardiovascular events by 20% in patients with established cardiovascular disease and obesity, independent of its glucose-lowering effects.

SELECT Trial Design

Patient Population

The SELECT trial enrolled 17,604 patients meeting strict criteria:

  • Age ≥45 years with established cardiovascular disease
  • BMI ≥27 kg/m² (obesity or overweight)
  • No history of type 1 or type 2 diabetes
  • Stable cardiovascular medications for ≥90 days

Randomisation and Dosing

Patients were randomised 1:1 to:

  • Semaglutide 2.4mg weekly (subcutaneous)
  • Placebo (matching vehicle)

Treatment continued for a median follow-up of 34 months, with mandatory lifestyle counselling in both groups.

Primary Results

Primary Endpoint Achievement

The semaglutide group demonstrated a statistically significant 20% reduction in the three-point MACE composite:

| Endpoint | Semaglutide | Placebo | Hazard Ratio | |----------|-------------|---------|-------------| | CV Death, MI, or Stroke | 6.5% | 8.0% | 0.80 (p<0.001) | | Non-fatal MI | 2.7% | 3.4% | 0.78 | | Non-fatal Stroke | 1.5% | 2.0% | 0.74 | | CV Death | 2.5% | 3.0% | 0.85 |

Weight Loss Results

Mean body weight reduction:

  • Semaglutide group: -9.4% at week 104
  • Placebo group: -0.9%
  • Treatment difference: -8.5% (p<0.001)

Secondary Endpoints

Significant improvements across cardiometabolic parameters:

  • Systolic blood pressure: -3.5 mmHg
  • Diastolic blood pressure: -1.5 mmHg
  • LDL cholesterol: -10% reduction
  • High-sensitivity CRP: -35% reduction
  • Waist circumference: -6.5 cm reduction

Mechanism of Cardiovascular Protection

Beyond Weight Loss

The SELECT trial's cardiovascular benefits exceed what would be expected from weight loss alone, suggesting direct cardiovascular effects:

#### Anti-inflammatory Effects

  • Significant CRP reductions independent of weight loss magnitude
  • IL-6 pathway modulation
  • Reduction in vascular inflammation markers
  • Potential anti-atherosclerotic mechanisms

#### Direct Cardiovascular Effects

GLP-1 receptors are expressed throughout the cardiovascular system:

  • **Heart**: Cardioprotective effects through reduced infarct size, improved cardiac output
  • **Blood vessels**: Endothelial function improvement, anti-atherosclerotic effects
  • **Kidney**: Reduced albuminuria, renal protection
  • **Liver**: NAFLD/NASH improvement, hepatic fat reduction

#### Metabolic Improvements

  • Improved insulin sensitivity
  • Favourable lipid profile changes
  • Reduced ectopic fat deposition
  • Blood pressure reduction

Clinical Implications

Expanded Indications

The SELECT trial supports semaglutide use for:

  • **Primary cardiovascular prevention** in high-risk obese patients
  • **Secondary cardiovascular prevention** in established CVD
  • **Weight management** with cardiovascular benefit
  • **Potential** broader indications (heart failure, CKD)

Treatment Guidelines

Major cardiovascular societies are updating guidelines to incorporate GLP-1 therapy for cardiovascular risk reduction:

  • ACC/AHA guidelines now include GLP-1 for CV risk reduction
  • ESC guidelines reference SELECT trial results
  • Professional societies emphasise multidisciplinary management

Research Applications

In Vitro Cardiovascular Research

Semaglutide research applications include:

  • Endothelial cell culture studies (0.01-100 nM)
  • Cardiomyocyte function assessment
  • Vascular smooth muscle proliferation studies
  • Inflammation marker quantification

In Vivo Preclinical Research

Preclinical models require:

  • Dietary-induced obesity models
  • Myocardial infarction models
  • Atherosclerosis models (ApoE-/-, Ldlr-/-)
  • Dosing: 0.05-0.5 mg/kg in rodents

Quality Standards

Rigorous cardiovascular research requires:

  • HPLC purity ≥99.5%
  • Mass spectrometry sequence verification
  • Endotoxin testing for cell culture
  • Batch-specific COA documentation
  • Proper storage (-20°C)

Future Directions

Ongoing Trials

The SELECT trial opens pathways for additional research:

  • Combination with SGLT2 inhibitors
  • Earlier intervention in obesity
  • Heart failure with preserved ejection fraction (HFpEF)
  • Chronic kidney disease
  • Neurodegenerative disease prevention

Next-Generation GLP-1 Research

Research is expanding beyond semaglutide:

  • Oral formulations (Rybelsus)
  • Dual GIP/GLP-1 agonism (tirzepatide)
  • Triple agonism (retatrutide)
  • Novel delivery mechanisms

ZePeptide provides research-grade semaglutide with complete analytical documentation for cardiovascular research programmes.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides